New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export NVS’s income statement to Excel — free account
Novartis AG
NVSHealthcare Drug Manufacturers General
Novartis AG’s revenue for fiscal 2025 (year ended December 2025) was $56.7 billion, up 9.57% from fiscal 2024.
- Revenue
- +4.67%
- EPS
- −68.8%
- Free cash flow
- −17.8%
- Total debt
- +53.9%
Quarter to September 2026, against a year earlier
151.95
0.74
+0.49%
Follow NVS
Alert me
Where the cash went Q3 FY2026, quarter to Sep 30, 2026
Free cash flow of $5.1B covered $1.7B of dividends and buybacks. Cash rose by $1.3B. What is a cash flow statement?
- Free cash flow
- $5.1B 92.9% of operating cash flow
- Returned to shareholders
- $1.7B 33.2% of free cash flow
- Debt, net
- −$768.0M repaid
- Change in cash
- +$1.3B over the period
| Operating cash flow | 5.5 |
|---|---|
| Capital expenditures | −0.4 |
| Free cash flow | 5.1 |
| Acquisitions, net | −1.1 |
| From investments, net | +0.1 |
| Buybacks, net | −1.7 |
| Debt repaid, net | −0.8 |
| Other | −0.4 |
| Change in cash | 1.3 |
Free cash flow
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Operating cash flow | $2.3B | $3.7B | $5.9B | $5.5B |
| Capex | −$608M | −$341M | −$295M | −$392M |
| Free cash flow | $1.7B | $3.3B | $5.6B | $5.1B |
Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Net Income |
1,196.00 | 3,257.00 | 3,156.00 | 2,404.00 |
+8 more quarters Free account |
Depreciation & Amortization |
3,543.00 | 1,406.00 | 1,208.00 | 1,536.00 | |
Non Cash Items (Other) |
2,576.00 | 1,238.00 | 366.00 | (975.00) | |
Accounts Receivable Change |
(170.00) | (256.00) | (504.00) | (94.00) | |
Change in inventories |
32.00 | 30.00 | (95.00) | 151.00 | |
Accounts Payable Change |
41.00 | (184.00) | (53.00) | 102.00 | |
Change in other assets and liabilities |
42.00 | 642.00 | (135.00) | (1,746.00) | |
Other operating activities |
(283.00) | (251.00) | (267.00) | (695.00) | |
Operating Cash Flow |
5,503.00 | 5,882.00 | 3,676.00 | 2,264.00 | |
Capital expenditures |
(392.00) | (295.00) | (341.00) | (608.00) | |
Change in intangibles (net) |
(350.00) | (413.00) | (485.00) | (296.00) | |
Net Aquisitions |
(1,067.00) | 399.00 | (12,043.00) | (30.00) | |
Short Term Investments Change (Net) |
7.00 | (303.00) | 1,099.00 | 11.00 | |
Long-Term Investments Change (Net) |
59.00 | 9.00 | 37.00 | (29.00) | |
Other investing activities |
(3.00) | (2,502.00) | (3.00) | (1,152.00) | |
Investing cash flow |
(1,746.00) | (3,105.00) | (11,736.00) | (2,104.00) | |
Repayment/Issuance of Debt (Net) |
(768.00) | 2,103.00 | 11,573.00 | 3,283.00 | |
Equity Repurchase (Common, Net) |
(1,698.00) | (1,185.00) | (1,875.00) | (1,476.00) | |
Dividends Paid (Total) |
0.00 | (2,871.00) | (6,197.00) | 0.00 | |
Other financial activities |
2.00 | (67.00) | 78.00 | (124.00) | |
Financing cash flow |
(2,464.00) | (2,020.00) | 3,579.00 | 1,683.00 | |
Exchange Rate Adjustment |
(39.00) | (18.00) | (77.00) | 36.00 | |
Change in Cash |
1,254.00 | 739.00 | (4,558.00) | 1,879.00 | |
Beginning Cash |
0.00 | 0.00 | 11,435.00 | 0.00 | |
Ending Cash |
1,254.00 | 739.00 | 6,877.00 | 1,879.00 | |
Stock Based Compensation |
267.00 | 267.00 | 303.00 | 299.00 | |
Dividends Paid (Common) |
0.00 | (2,871.00) | (6,197.00) | 0.00 | |
Net Cash/Marketcap |
0.00 | 0.00 | 0.00 | 0.00 | |
Assets Liabilities Change (Total) |
(1,529.00) | 232.00 | (787.00) | (6.00) | |
Investments Change (Net) |
66.00 | (294.00) | 1,136.00 | (18.00) | |
Issuance/Purchase of Shares |
(1,698.00) | (1,185.00) | (1,875.00) | (1,476.00) |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026